Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | STAT3 | P40763 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | MMP13 | P45452 | 1/20 | 0.33 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.32 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.32 |
| ▸ | PSEN1 | P49768 | 3/20 | 0.31 |
| ▸ | PSEN2 | P49810 | 3/20 | 0.31 |
| ▸ | APH1B | Q8WW43 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3116629 | 1.00 | CA12 (0.36) | CA12CA2CA9ALDH1A1STAT3 | |
| SCHEMBL7213256 | 1.00 | CA12 (0.36) | CA12CA2CA9ALDH1A1STAT3 | |
| SCHEMBL3117255 | 1.00 | CA12 (0.36) | CA12CA2CA9ALDH1A1STAT3 | |
| SCHEMBL3122917 | 0.94 | PLA2G2C (0.34) | CA12CA2CA9ALDH1A1STAT3 | |
| SCHEMBL3123597 | 0.93 | PLA2G2C (0.36) | CA12CA2CA9ALDH1A1STAT3 | |
| SCHEMBL3118259 | 0.93 | PLA2G2C (0.36) | CA12CA2CA9ALDH1A1STAT3 | |
| SCHEMBL27486951 | 0.93 | PLA2G2C (0.36) | CA12CA2CA9ALDH1A1STAT3 | |
| SCHEMBL4374409 | 0.91 | KMT2A (0.35) | CA2ALDH1A1STAT3MEN1KMT2A | |
| SCHEMBL3831947 | 0.91 | KMT2A (0.35) | CA2ALDH1A1STAT3MEN1KMT2A | |
| SCHEMBL3116664 | 0.91 | KMT2A (0.35) | CA2ALDH1A1STAT3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1192125-B9 | MONO-SUBSTITUTED 3-PROPYL GAMMA-AMINOBUTYRIC ACIDS | WARNER LAMBERT CO (US) | 2009-09-16 | — | — | EP | disclosed |
| US-20090203782-A1 | Alpha 2 Delta Ligands for Fibromyalgia and Other Disorders | PFIZER INC. | 2009-08-13 | — | — | US | disclosed |
| EP-1192125-B1 | MONO-SUBSTITUTED 3-PROPYL GAMMA-AMINOBUTYRIC ACIDS | WARNER LAMBERT CO (US) | 2008-12-31 | — | — | EP | disclosed |
| US-20080207755-A1 | Alpha 2 Delta Ligands For Fibromyalgia and Other Disorders | PFIZER INC | 2008-08-28 | — | — | US | disclosed |
| US-7381747-B2 | Alpha 2 delta ligands for post-traumatic stress disorder | WARNER-LAMBERT COMPANY LLC (US) | 2008-06-03 | — | — | US | disclosed |
| EP-1840117-A1 | Mono- and disubstituted 3-propyl gamma-aminobutyric acids | Warner-Lambert Company LLC (US) | 2007-10-03 | — | — | EP | disclosed |
| US-7189747-B2 | Method of treating noninflammatory cartilage damage | WARNER-LAMBERT COMPANY (US) | 2007-03-13 | — | — | US | disclosed |
| US-20070027212-A1 | ALPHA 2 DELTA LIGANDS FOR FIBROMYALGIA AND OTHER DISORDERS | PFIZER INC | 2007-02-01 | — | — | US | disclosed |
| US-7164034-B2 | Alpha2delta ligands for fibromyalgia and other disorders | PFIZER INC. (US) | 2007-01-16 | — | — | US | disclosed |
| US-7138542-B2 | Method of treating tinnitus | WARNER LAMBERT COMPANY (US) | 2006-11-21 | — | — | US | disclosed |
| US-20040063789-A1 | Mono-and disubstituted 3-propyl gamma-aminobutyric acids | BELLIOTTI THOMAS RICHARD (US) | 2004-04-01 | — | — | US | disclosed |
| US-6642398-B2 | Improving drug qualities such as bioavailability and stability | WARNER-LAMBERT COMPANY | 2003-11-04 | — | — | US | disclosed |
| US-20030181523-A1 | Mono-and disubstituted 3-propyl gamma-aminobutyric acids | BELLIOTTI THOMAS RICHARD (US) | 2003-09-25 | — | — | US | disclosed |
| US-20030176504-A1 | Method of treating tinnitus | DOOLEY DAVID JAMES (US) | 2003-09-18 | — | — | US | disclosed |
| US-6620829-B2 | Administering a therapeutically effective amount of a GABA analog having characteristic of being an inhibitor of cartilage damage, or a pharmaceutically acceptable salt | WARNER-LAMBERT COMPANY | 2003-09-16 | — | — | US | disclosed |
| WO-2003063845-A1 | ALPHA 2 DELTA LIGANDS TO TREAT TINNITUS | WARNER-LAMBERT COMPANY LLC (US) | 2003-08-07 | — | — | WO | disclosed |
| US-20020072533-A1 | Method of treating cartilage damage | SCHRIER DENIS (US) | 2002-06-13 | — | — | US | disclosed |
| EP-1199072-A2 | Method of treating cartilage damage | WARNER-LAMBERT COMPANY (US) | 2002-04-24 | — | — | EP | disclosed |
| EP-1192125-A2 | MONO- AND DISUBSTITUTED 3-PROPYL GAMMA-AMINOBUTYRIC ACIDS | WARNER-LAMBERT COMPANY (US) | 2002-04-03 | — | — | EP | disclosed |
| WO-2000076958-A2 | MONO- AND DISUBSTITUTED 3-PROPYL GAMMA-AMINOBUTYRIC ACIDS | WARNER-LAMBERT COMPANY (US) | 2000-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203782-A1 | Alpha 2 Delta Ligands for Fibromyalgia and Other Disorders | OPRD1, OPRL1, FFAR3 | CA12 2514/4885CA2 327/4885CA9 2901/4885 |
| US-20030176504-A1 | Method of treating tinnitus | ADRA2A, ADRA1A, ADRA1D | CA12 1737/4885CA2 632/4885CA9 1774/4885 |
| US-20020072533-A1 | Method of treating cartilage damage | COL2A1, COL1A1, GABRB1 | CA12 474/4885CA2 205/4885CA9 325/4885 |
| US-20070027212-A1 | ALPHA 2 DELTA LIGANDS FOR FIBROMYALGIA AND OTHER DISORDERS | OPRD1, HCRTR2, OPRL1 | CA12 2292/4885CA2 977/4885CA9 3181/4885 |
| US-20080207755-A1 | Alpha 2 Delta Ligands For Fibromyalgia and Other Disorders | OPRD1, OPRL1, FFAR3 | CA12 2514/4885CA2 327/4885CA9 2901/4885 |
| US-20040063789-A1 | Mono-and disubstituted 3-propyl gamma-aminobutyric acids | GABRB1, GABRA1, GABRB3 | CA12 2849/4885CA2 1813/4885CA9 2468/4885 |
| US-20030181523-A1 | Mono-and disubstituted 3-propyl gamma-aminobutyric acids | GABRB1, GABRA1, GABRB3 | CA12 2849/4885CA2 1813/4885CA9 2468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.